Adial PharmaceuticalsADIL
13F holders, Q1 2026 (March 31)15holders +14
2new positions
0sold out
$1.79avg. 13F price*
At the end of Q1 2026, 15 institutions reported holding Adial Pharmaceuticals Inc. (ADIL) in their 13F filings, up 14 from Q4 2025. 2 opened new positions and 0 sold out. The largest holders were Geode Capital Management, LLC ($43K), Vanguard Fiduciary Trust Co. ($11K) and Manchester Capital Management LLC ($3K).
- Company
- Adial Pharmaceuticals Inc.
- CUSIP
- 00688A304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $34 |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 19,566 shares bought and 2,011 shares sold, net +17,555 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Geode Capital Management, LLC | 0.00% | Add +289.2% | 24,249 | $43K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 5,879 | $11K |
| Manchester Capital Management LLC | 0.00% | No change | 1,923 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +2428.0% | 1,356 | $2K |
| BlackRock, Inc. | 0.00% | No change | 1,110 | $2K |
| UBS Group AG | 0.00% | Add +47.8% | 542 | $970 |
| Vanguard Capital Management LLC | 0.00% | — | 361 | $646 |
| Raffa Wealth Management, LLC | 0.00% | Reduce -96.0% | 83 | $149 |
| Morgan Stanley | 0.00% | Add +13788.9% | 50 | $90 |
| SBI Securities Co., Ltd. | 0.00% | Add +1.5% | 47 | $84 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 15 | $27 |
| Wells Fargo & Company | 0.00% | Reduce -6.3% | 6 | $11 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 4 | $7 |
| Harbour Investments, Inc. | 0.00% | Reduce -24.2% | 3 | $5 |
| Abound Wealth Management | 0.00% | Reduce -7.4% | 1 | $2 |
"% of holder's portfolio" is ADIL's weight in each manager's 13F, not the share of Adial Pharmaceuticals Inc. the manager owns.